Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Desipramine hydrochloride is administered orally. Although desipramine has been administered in up to 3 divided doses throughout the day, it is long-acting and the entire daily dose may be administered at one time. Administration of the entire daily dose at bedtime may reduce daytime sedation; patients who experience insomnia and stimulation from the drug may receive the entire daily dose in the morning.
There is a wide range of dosage requirements, and dosage of desipramine hydrochloride must be carefully individualized. Initial dosages in adults should be low and generally range from 75-150 mg daily, depending on the severity of the condition being treated. Dosage may be gradually adjusted to the level that produces maximal therapeutic effect with minimal toxicity. In seriously ill patients, desipramine dosage may be gradually increased to 300 mg daily if necessary. Desipramine hydrochloride dosages exceeding 300 mg daily are not recommended. Hospitalized patients under close supervision may generally be given higher doses than outpatients. Geriatric and adolescent patients should usually be given lower than average doses. Manufacturers state that therapy should be initiated with 25-50 mg daily in these patients and that dosages greater than 100 mg daily are usually not necessary. In geriatric and adolescent patients who are seriously ill, desipramine dosage may be further increased to 150 mg daily if necessary. Desipramine hydrochloride dosages exceeding 150 mg daily are not recommended in these age groups. Maximum antidepressant effects may not occur for 2 or more weeks after therapy is begun.
After symptoms are controlled, dosage should be gradually reduced to the lowest level that will maintain relief of symptoms. To avoid the possibility of precipitating withdrawal symptoms, desipramine should not be terminated abruptly in patients who have received high dosages for prolonged periods.
Patients should be monitored for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment.
Desipramine shares the pharmacologic actions, uses, and toxic potentials of the tricyclic antidepressants, and the usual precautions of tricyclic antidepressant administration should be observed. Patients should be fully advised about the risks, especially suicidal thinking and behavior (suicidality), associated with tricyclic antidepressant therapy. For a complete discussion, and , in the Tricyclic Antidepressants General Statement 28:16.04.28.
Desipramine should be used with extreme caution in patients with preexisting cardiovascular disease because of the possibility of conduction defects, arrhythmias, tachycardia, strokes, and acute myocardial infarction. The drug should also be used with extreme caution in patients with a family history of sudden death, cardiac dysrhythmias, or cardiac conduction disturbances. In addition, overdosage with desipramine has resulted in a higher death rate compared with overdosages of other tricyclic antidepressants. For a complete discussion on the cardiovascular effects of tricyclic antidepressants, and , in the Tricyclic Antidepressants General Statement 28:16.04.28. For a complete discussion on the pathogenesis, manifestations, and treatment of overdosage due to tricyclic antidepressants,
Because collapse and sudden death occurred in at least one child (an 8-year-old boy) receiving desipramine for 2 years for attention deficit hyperactivity disorder (ADHD) and sudden death also has been reported in other children receiving the drug, at least one manufacturer of desipramine recommends that the drug not be used in children. Although a causal relationship between the use of desipramine and the risk of sudden death has not been established, many clinicians recommend that desipramine not be used in children with this disorder when tricyclic antidepressant therapy is contemplated.
The US Food and Drug Administration (FDA) also has determined that antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with major depressive disorder and other psychiatric disorders. However, FDA also states that depression and certain other psychiatric disorders are themselves associated with an increased risk of suicide. Anyone considering the use of desipramine in a child or adolescent for any clinical use must therefore balance the potential risk of therapy with the clinical need. ( and , in the Tricyclic Antidepressants General Statement 28:16.04.28.)
Geriatric patients may be at risk of drug-induced toxicity when treated with desipramine, a tricyclic antidepressant that is known to be eliminated mainly by the kidneys. In this patient population, the ratio of plasma concentrations of the principal metabolite, 2-hydroxydesipramine, to desipramine appears to be increased, most likely because of decreased renal elimination that occurs with aging. Therefore, particular attention should be paid to desipramine dosage and it may be useful to monitor renal function in these patients. Desipramine use in geriatric patients also has been associated with an increased risk of falling and mental confusion.
Desipramine hydrochloride appears to be well absorbed from the GI tract. Peak plasma concentrations occur within 4-6 hours after oral administration.
Limited data indicate that desipramine is distributed into milk in concentrations similar to those present in maternal plasma.
The plasma half-life of desipramine ranges from 7 to longer than 60 hours. Desipramine is metabolized principally via oxidation to 2-hydroxydesipramine, which retains some of the parent compound's ability to block the uptake of amines and may have particularly prominent cardiac depressant activity.